Skip to main content

454 Says Q3 Revenues Surge 70 Percent; CuraGen Still Mulls Its Stake

NEW YORK (GenomeWeb News) — 454 Life Sciences today said third-quarter revenue increased 70 percent to $9.9 million from $5.8 million year over year.
 
The CuraGen subsidiary said 454 made $4.8 million from sales of instruments and reagents and $2.8 million from sequencing service revenue. The remainder came from grants and other sources, the company said.
 
CuraGen said it is still working with Goldman Sachs to review options for 454’s future. In August, GenomeWeb News reported that the company had hired Goldman Sachs to help it develop strategies for its stake in 454.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.